UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 30TH
SEPTEMBER, 2005
PARTICULARS
3 months
3 months
6 months
6 months
Year
ended
ended
ended
ended
Ended
30.09.2005
30.09.2004
30.09.2005
30.09.2004
31.3.2005
Unaudited
Unaudited
Unaudited
Unaudited
Audited
Net Sales/Operational Income
8027.62
4548.05
16025.07
8948.05
23944.93
Others Income
45.19
8.07
63.96
32.44
57.50
TOTAL EXPENDITURE :
6538.64
3439.34
13060.04
7203.87
19582.77
(a) Increase/decrease in stock
in trade
(753.15)
(552.27)
(842.30)
(880.91)
(932.80)
(b) Consumption of Raw Material
5810.18
3014.39
11192.47
6088.62
16300.63
(c) Staff Cost
155.04
87.41
290.00
178.29
441.83
(d) Other expenditure
1326.57
889.81
2419.87
1817.85
3773.11
Interest
280.28
160.61
515.62
363.43
830.54
Depreciation
202.89
93.28
349.72
182.98
409.85
Profit before tax
1051.01
862.88
2163.65
1230.21
3179.27
Provision for taxation
88.53
67.66
182.07
96.46
260.27
Net Profit before Deferred Tax
962.48
795.22
1981.58
1133.75
2919.00
Provision for deferred tax
133.47
92.92
147.14
145.50
271.04
Provision for Fringe Benefit Tax
2.00
0.00
3.00
0.00
0.00
Net Profit
827.01
702.30
1831.44
988.25
2647.96
Paid up Equity Share Capital
2090.00
1561.37
1840.00
Reserve excluding revaluation
reserves
15080.58
4570.00
8874.14
EPS (not Annualised) Rs. Basic
4.44
4.50
9.83
6.33
16.17
Diluted
4.24
4.50
9.40
6.33
15.64
Aggregate of Non-Promoter
Shareholding
No. of Shares
15504594
9779594
13004594
%
of Shareholding
74.18%
62.63%
70.68%
Notes:
a) During the quarter under review the total
turnover of company increased by 76.51% whereas the Export turnover increased by
33.07%. The net profit after tax increased by 17.76% over the corresponding figures
of previous year quarter.
b) During the quarter, company raised a sum
of US$ 10.625 mns through the GDR offering (2500000 GDRs each GDR representing one
equity share) which now stands listed at the Luxembourg Stock Exchange.
c) Full Commercial production has started at
Company’s two new dedicated manufacturing blocks at Derabassi facility and
at new API facility at Samba Jammu, after the successful initial validation batches.
The results from the new units will be reflected in the next quarter onwards.
d) Company’s new state of the art Research
& Development Centre at Mohali, Punjab, is nearing completion and will be put
to operation in the next quarter.
e) The R&D of the Company has filed 52 DMFs
with different International Regulatory Authorities of various Countries.
f) During the Quarter, the Company has achieved
a two Star Export House Status.
g) Information on Investor Complaints for the
quarter: Opening Balance Nil, Received Nil, Redressed Nil, closing Balance Nil.
h) The previous period figures have been re-grouped
and re-arranged wherever necessary.
i) The Company is exclusively in the Pharmaceutical
business segment.
j) The above results were taken on record by
the Board of Directors in its meeting held on 22nd October, 2005.
For Ind-Swift Laboratories Limited
Sd/-
Sd/-
Place:Chandigarh
(N.R.MUNJAL)
(V.K.MEHTA)
Date: 22th October, 2005
Managing Director
Jt.Managing Director
To know about our Formulation Division, please visit us at Ind-Swift Limited, our other
group company.
